Targeting the subtypes of breast cancer: Rethinking investigational drugs

Expert Opinion on Investigational Drugs

Volumn 21, Issue 2, 2012, Pages 191-204

  Curigliano, Giuseppe ^a   Locatelli, Marzia ^a   Fumagalli, Luca ^a   Brollo, Janaina ^a   Munzone, Elisabetta ^a   Nolé, Franco ^a   Criscitiello, Carmen ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer subtypes; Early breast cancer; Investigational drugs

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BOSUTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FIGITUMUMAB; GEFITINIB; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NERATINIB; OLAPARIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTRELISIB; PLACEBO; RIDAFOROLIMUS; SARACATINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VORINOSTAT; XL 147; XL 765; XL 999;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; HUMAN; MONOTHERAPY; NONHUMAN; REVIEW;

BREAST NEOPLASMS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84855811750     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.651456     Document Type: Review

References (79)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;21:747-52.
2. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23
3. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7
4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74 (Pubitemid 39100473)
5. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279
6. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27:1168-76
7. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50
8. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39 (Pubitemid 351538762)
9. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of triple negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:454-63
10. Phipps AI, Buist DS, Malone KE, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011;22:399-405
11. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
12. Dignam JJ, Dukic V, Anderson SJ, et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009;116:595-602
13. Aebi S, Sun Z, Braun D, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011. [Epub ahead of print]
14. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65
15. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8
16. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800
17. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464(7291):999-1005
18. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789-99 (Pubitemid 39070849)
19. Parmigiani G, Boca S, Lin J, et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009;93(1):17:1-8
20. Hanahan D, Weinberg RA. Hallmarks of Cancer: the next generation. Cell 2011;144(5):646-74.
21. Goldhirsch A, Wood WC, Coates AS, et al. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22(8):1736-47
22. Curigliano G, Bagnardi V, Viale G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011. [Epub ahead of print
23. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9 (Pubitemid 26300127)
24. Martin LA, Farmer I, Johnston SR, et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68 (Pubitemid 36994549)
25. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 2011;145(1):19-24
26. Albain K, Elledge R, Gradishar WJ, et al. Open-label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76:A20
27. Baselga J, Albanelli J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-33 (Pubitemid 46206986)
28. Robertson JFR, Gutteridge E, Cheung KL, Cheung Eet al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM) resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Annu Meet Am Soc Clin Oncol 2003;22:7
29. Mita M, Bono J, Mita A. A phase II and biologic correlative study investigating anastrozole (A) in combination with gefitinib (G) in postmenopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy. Breast Cancer Res Treat 2005;94:abstract 1117
30. Mayer I, Ganja N, Shyr Y, et al. A phase II trial of letrozole plus erlotinib in post-menopausal women with hormone-sensitive metastatic breast cancer: preliminary results of toxicities and correlative studies. Breast Cancer Res Treat 2006;100:abstract 4052
31. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neo adjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22 (Pubitemid 47477255)
32. Polychronis A, Sinnet HD, Hadjiminas D, et al. Pre-operative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal growth factor receptor positive primary breast cancer: a double blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6:383-91 (Pubitemid 40753744)
33. Osborne CK, Dirix L, Mackey J, et al. Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007;106(Suppl):abstract 2067
34. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16(6):1904-14
35. Mauriac L, Cameron D, Dirix L, et al. Results of randomised phase II trial combining Iressa (gefitinib) and Arimidex in women with advanced breast cancer. EORTC protocol 10021. Cancer Res 2009;69(Supp 12):abstract 6133
36. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9 (Pubitemid 46294957)
37. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study. J Clin Oncol 2009;27:5529-37
38. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
39. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-91
40. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
41. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23(23):5314-22 (Pubitemid 46206985)
42. Ferguson AT, Lapidus RG, Baylin SB, et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279-83
43. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104(12):1828-35
44. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:423-9
45. Chakraborty AK, Welsh A, Digiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010;120:327-35
46. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83
47. Kaufman PA, Ferrero JM, Bourgeois H, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Research 2010;70:76s
48. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300
49. Hiscox S, Morgan L, Green TP, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74 (Pubitemid 43945756)
50. Riggins RB, Thomas KS, Ta HQ, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006;66:7007-15 (Pubitemid 44197676)
51. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44 (Pubitemid 47517638)
52. Mayer EL, Baurain JF, Sparano J, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011 Nov 1; 17(21):6897-904
53. Edwards DP, Wardell SE, Boonyaratanakornkit V. Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. J Steroid Biochem Mol Biol 2002;83(1-5):173-86 (Pubitemid 37040654)
54. Zabrecky JR, Lam T, McKenzie SJ, et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20 (Pubitemid 21908361)
55. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27 (Pubitemid 39485684)
56. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7 (Pubitemid 34048651)
57. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82
58. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96
59. Tin-Wein Y, Bai L, Clade D, et al. The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. PNAS 2002;12:7968-73 (Pubitemid 34650989)
60. Tadayoni M, Bourret LA, Liu C, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. PNAS 1996;93:8618-23 (Pubitemid 26269609)
61. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
62. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405
63. ClinicalTrials.gov. An Open-Label Study of Trastuzumab-MCC-DM1 (TDM1) vs. Capecitabine Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA). Available from: http:/clinicaltrials.gov/ show/NCT00829166, [Accessed 28 May 2011]
64. ClinicalTrials.gov. A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available from: http://clinicaltrials.gov/ct2/show/NCT01120184, [Accessed 28 May 2011]
65. Adams CW, Allison DE, Flagella K, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-27
66. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28(7):1131-7
67. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
68. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere)" [abstract S3-2]. San Antonio. Breast Cancer Symposium; 2010
69. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer [abstract S3-3]. 33rd Annual San Antonio Breast Cancer Symposium; 10 December 2010
70. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28(8):1301-7
71. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann Oncol 2011;22:268-79
72. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
73. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005:434;917-21 (Pubitemid 40559006)
74. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376(9737):235-44
75. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(7):1145-53
76. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364(3):205-14
77. ClinicalTrials.gov. Phase 3, multi-center, open-label, randomized study of gemcitabine/carboplatin, with or without iniparib, in patients with ER-, PR-, and HER2-negative metastatic breast cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01130259, [Accessed 28 May 2011
78. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29(Suppl):abstract 1007
79. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract 1019]. J Clin Oncol 2009;28 (15S, Part 1):118s